藥品參考
Erdafitinib
Erdafitinib is a medicine in the class oncology. It is used for bladder cancer.
- 藥物類別: Oncology
- 用途: bladder cancer
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01EN01
- 常見劑型
- 錠劑
- 已知交互作用
- 124 (嚴重: 22 · 中度: 72 · 輕微: 30)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Kinase inhibitor that binds to and inhibits enzymatic activity of FGFR1, FGFR2, FGFR3 and FGFR4 (in vitro data); inhibits FGFR phosphorylation and signaling and decreases viability of cell lines with FGFR alterations.
成人常用劑量（仿單摘要）
Locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations: 8 mg orally once daily; increase to 9 mg once daily based on tolerability, including hyperphosphatemia, at 14 to 21 days; continue until disease progression or unacceptable toxicity
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: in rats it caused malformations and embryo-fetal death below human exposure. No human data. Verify pregnancy status; women, and men with female partners, use effective contraception during and for 1 month after.
- 哺乳
- Unsafe No milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose.
已通報的副作用
- Increased phosphate
- Nail disorders
- Stomatitis
- Diarrhea
- Fatigue
- Dry mouth
禁忌症
- None.
哪些人需要特別留意
- Ocular disorders including CSR/RPED (22%) and dry eye; monthly eye exams for first 4 months then every 3 months, and urgently for visual symptoms; dry eye prophylaxis.
- Hyperphosphatemia and soft tissue mineralization; monitor phosphate, restrict dietary phosphate to 600–800 mg daily, consider phosphate binder if above 7.0 mg/dL.
- Embryo-fetal toxicity; verify pregnancy status and use effective contraception during treatment and for one month after last dose.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (124)
- Amobarbital + Erdafitinib Major
- Apalutamide + Erdafitinib Major
- Carbamazepine + Erdafitinib Major
- Chloramphenicol + Erdafitinib Major
- Clarithromycin + Erdafitinib Major
- Colchicine + Erdafitinib Major
- Dabigatran etexilate + Erdafitinib Major
- Efavirenz + Erdafitinib Major
- Enzalutamide + Erdafitinib Major
- Erdafitinib + Fluconazole Major
同類別的其他藥品
常見問題
What is Erdafitinib used for?
Erdafitinib is a medicine in the class oncology. It is used for Bladder cancer.
What side effects have been reported with Erdafitinib?
Increased phosphate, Nail disorders, Stomatitis, Diarrhea, Fatigue, Dry mouth.
Can Erdafitinib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: in rats it caused malformations and embryo-fetal death below human exposure. No human data. Verify pregnancy status; women, and men with female partners, use effective contraception during and for 1 month after. Breastfeeding: Unsafe. No milk data. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose.
What does Erdafitinib interact with?
MediHelp lists 124 known interactions for Erdafitinib. Major: 22 · Moderate: 72 · Minor: 30. The most serious include Amobarbital, Apalutamide, Carbamazepine.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
